We describe two mouse monoclonal antibodies reactive with lipopolysaccharide derived from the J5 mutant of Escherichia coli 0111:B4. These antibodies react with purified lipopolysaccharide derived from rough mutants of E. coli and Salmonella typhimurium and also with lipopolysaccharide associated with both smoothand rough-phenotype, gram-negative bacteria. Both antibodies appear to bind determinants present in the lipopolysaccharide core region, and this reactivity is inhibited in the presence of polymyxin B. Although their patterns of reactivity differ, both antibodies exhibit extensive serological cross-reactivity with a variety of gram-negative bacteria. Reagents of this type should prove useful in animal models to delineate the requisite affinity, epitope specificity, immunoglobulin class, etc., needed for the prevention and treatment of gram-negative bacteremia.
A number of studies in animal models (1-3, 11, 12, 17, 18, 24) and in humans (25) have indicated that antibodies specific for the core region of lipopolysaccharide (LPS) are cross-reactive with LPS derived from a variety of gram-negative organisms. In these studies, rough mutants of Escherichia coli and Salmonella minnesota, or the LPS derived from them, were employed for the production of anti-core antibodies. These mutants possess enzyme defects that render them unable to incorporate the immunodominant oligosaccharide side chains onto the core region of the LPS molecule. Antibodies reactive with LPS core determinants have been shown to protect against the lethal effects of LPS or gram-negative infection from E. coli (2, 18, 24, 25) , Salmonella typhosa (12) , Klebsiella pneumoniae (24) , Pseudomonas aeruginosa (1), Neisseria meningitidis (3), and Haemophilus influenzae (17) . Anti-core antibodies are thought to offer protection against gram-negative infection and endotoxemia by virtue of the known structural similarities among the core regions of serologically unique LPS molecules (16) .
In this report we describe the production and characterization of mouse monoclonal antibodies reactive with core determinants present on LPS molecules derived from the J5 mutant of E. coli 0111:B4. We describe the fine specificity of these antibodies and demonstrate their extensive serological cross-reactivity on LPS associated with gram-negative clinical isolates. These antibodies should be useful in future studies aimed at determining the therapeutic and diagnostic utility of monoclonal anti-core antibodies.
MATERIALS AND METHODS Reagents. LPS was purchased from List Biological Laboratories, (Campbell, Calif.) or Ribi ImmunoChem Research, Inc. (Hamilton, Mont.) or were obtained from Thomas Tachovsky (Cambridge Research Laboratory) and Richard Ulevitch (Scripps Clinic and Research Foundation). LPS derived from rough and smooth strains of bacteria were prepared by established methods (6, 23 LPS derived from an Re mutant of Salmorella typhimurium, G30/C21, inhibited the reactivity of both anti-J5 monoclonal antibodies, and the level of inhibition was equivalent to that obtained with J5 LPS. MAb 49-2-biB required approximately 100-fold less Re LPS than did MAb 48-1-lOC to achieve comparable levels of inhibition. LPS derived from the smooth parental strain S. typhimurium was non-inhibitory in a fashion similar to that observed with O111:B4 LPS.
The results presented in Tables 1 and 2 indicate that, although both anti-J5 monoclonal antibodies react with J5 E. coli LPS and with LPS derived from an Re mutant of S. typhimurium, they are not reactive with LPS derived from either the parental, smooth homologous strain (0111:B4 E. coli) or heterologous strain (S.. typhimluriurn wild type).
Competition assays were performed to ascertain whether the two anti-J5 monoclonal antibodies reacted with the same epitope. Wells of PVC trays were coated with J5 LPS, and unlabeled antibody preparations were utilized to inhibit the binding of 20 ng of radiolabeled MAb 48-1-lOC or MAb 49-2-1iB with the solid-phase antigen (Table 3) . Although both anti-J5 monoclonal antibodies inhibited each other's reactivity, MAb 49-2-1iB was a more effective inhibitor, on a weight basis, than MAb 48-1-bOC in both the homologous and heterologous competition assays. Unlabeled MAb 49-2-biB was able to completely displace labeled MAb 48-1-IOC (97% inhibition at 62.5 ng), whereas unlabeled MAb 48-1-lOC was unable to effect 50% inhibition of binding of radiolabeled MAb 49-2-biB (39% inhibition at 1,000 ng). These results are most likely due to affinity differences Tables 2 and 3 , which suggested the higher affinity of MAb 49-2-1iB compared with that of MAb 48-1-10C.
Two additional monoclonal antibodies were utilized as controls for the polymyxin B inhibition studies. Antibodies derived from hybridoma 24-8-8G react with the 0-somatic antigen of 055:B5 LPS, whereas antibodies derived from hybridoma 2-18-11 are of the same immunoglobulin subclass as the anti-J5 antibodies (IgG2b) and react with the Ar hapten. Polymyxin B did not inhibit the binding of either control monoclonal antibody ( Table 4 ). The ability of LPS derived from smooth E. coli strain 055:B5 to partially inhibit Table 5 for E. coli. Although there was a certain degree of day-to-day variability in the whole organism ELISA, the data shown are representative of those observed on a number of occasions. In our hands, ELISA optical density values of -0.100 are considered to represent positive reactivity of antibody with heat-killed organisms. In most cases, the reactivity of both antibodies with the various clinical isolates of E. coli paralleled one another. One exception is E. coli clinical isolate no. 11, which appeared to be more reactive with MAb 48-1-10C than with MAb 49-2-liB. In general, the reactivity of both monoclonal antibodies was somewhat lower with the clinical isolates than with the J5 bacterial cells or the parental strain 0111:B4 cells. Culture media and a hybridoma culture supernatant containing anti-Ar MAb 2-18-11 were completely unreactive in the assay (data not shown).
Both anti-J5 monoclonal antibodies were assayed against a variety of non-E. coli, gram-negative clinical isolates (Table 6) The reactivity of monoclonal antibodies was determined by ELISA.
DISCUSSION
The purpose of the present study was to produce monoclonal antibodies reactive with LPS core structures common among Enterobacteriaceae. A number of points can be made concerning the serological reactivity of the two anti-J5 monoclonal antibodies described in this report. These antibodies react with purified, rough LPS and with LPS associated with both rough and smooth heat-killed organisms (Table 1) , but are unreactive with purified LPS derived from smooth strain organisms (Table 2) . Even LPS derived from the J5 parental strain, E. coli 0111:B4, is unreactive with both antibodies.
The inability of anti-J5 MAb to react with smooth-strain LPS is most likely the result of the core epitopes being blocked by oligosaccharide side chains present to various degrees on wild-type LPS. Since these antibodies are reactive with LPS when associated with heat-killed, smoothstrain organisms (Tables 1, 5 , and 6), it is apparent that this method of cell preparation somehow helps to unmask LPS core determinants present on the surface of bacteria. It is unclear at present whether heat treatment of smooth organisms exposes core determinants present on those LPS molecules possessing a full complement of oligosaccharide side chains or whether it simply affords accessibility to those LPS molecules present at a stage in assembly when they have not yet become associated with the side chains (9, 20) . Heat treatment of purified, smooth LPS was unsuccessful in exposing core determinants as determined by direct binding studies (heat-treated LPS as a solid phase antigen) and inhibition studies (heat-treated LPS as an inhibitor of binding of MAb with solid phase J5 LPS) (M. Nelles, unpublished observations).
J5 LPS is characterized as being of the Rc chemotype and therefore contains ethanolamine, KDO, phosphate, heptose, glucose, and lipid A (4) . The data presented in Table 3 demonstrate that neither heptose nor glucose contributes to the reactivity with either MAb since LPS derived from an Re mutant of S. typhimurium (which is comprised solely of KDO, phosphate, ethanolamine, and lipid A) is equivalent quantitatively to J5 LPS in its reactivity with both antibodies (Table 2) .
The data shown in Table 4 indicate that polymyxin B specifically inhibits the interaction between the anti-core monoclonal antibodies and J5 LPS. Control experiments indicated that the inhibition resulted from the polymyxin B binding to LPS rather than to the anti-LPS antibodies. In addition, polymyxin B exerted no effect on the reactivity of a monoclonal antibody specific for the 0-somatic antigens of 055:B5 LPS.
Although polymyxin B is known to react with both the lipid A region of LPS (19) and with the KDO present in the inner core region (21), we favor the interpretation that both monoclonal antibodies are reactive with the core portion of the LPS molecule. First, a number of studies have indicated that one must immunize animals with acid-hydrolyzed lipid A coated onto bacteria to produce an antibody response against lipid A (2, 7, 11) . Immunization with either purified rough LPS or rough organisms results in an antibody response directed solely toward the non-lipid A region of the molecule. The mice from which both hybridomas were derived had been immunized with J5 cells. Second, experiments employing lipid A as either a solid-phase antigen in direct binding studies, or as an inhibitor to prevent reactivity of anti-core antibodies with solid phase J5 LPS, were uniformly negative (M. Nelles, unpublished observations).
The data presented in Table 3 seem to indicate, upon first inspection, that both antibodies are reactive with the same core epitope by virtue of the ability of MAb 49-2-liB to inhibit radiolabeled MAb 48-1-10C from binding to solidphase J5 LPS. These results can also be explained by two antibodies possessing different affinities and reacting with distinct core epitopes located in close proximity to one another. Although both antibodies show qualitatively similar patterns of reactivity against the E. coli clinical isolates tested (Table 5) , their patterns of reactivity against non-E. coli clinical isolates are quite different (Table 6 ). Based on these results, we favor the idea that MAb 48-1-10C and 49-2-1iB react with different core determinants.
Although the anti-J5 monoclonal antibodies described in this report do not react with purified LPS preparations containing oligosaccharide side chains (i.e., "smooth" LPS), they are reactive with LPS associated with laboratory strains (Table 1) and clinical isolates (Tables 5 and 6 ) of gram-negative bacteria. Both antibodies exhibit comparable patterns of serological reactivity against E. coli clinical isolates (Table 5) . Studies utilizing a variety of non-E. coli, gramnegative clinical isolates (Table 6 ) demonstrated the preferential reactivity of one of the antibodies (MAb 48-1-10C ).
Despite the different patterns of reactivity, it is clear that both monoclonal antibodies react with epitopes that are conserved among members of the Enterobacteriaceae. Studies are in progress to more fully assess the extent of the cross-reactivity among gram-negative organisms and to determine the structural basis for the differences in reactivity between MAb 48-1-lOC and MAb 49-2-liB. In addition, experiments are underway which are designed to determine the reasons for anti-J5 monoclonal antibodies reacting with smooth LPS associated with heat-killed organisms, but not with purified smooth LPS.
Our inability to demonstrate serological reactivity of anticore antibodies with smooth LPS is not a new finding. Previous studies (10) protection studies, they do indicate that monoclonal anti-core antibodies react with LPS in a fashion equivalent to that of polyclonal antibodies that have been used effectively in a therapeutic manner both in animal models (1-3, 11, 12, 17, 18, 24) and in humans (25) . In conclusion, the results presented in this report lend support to the concept of conserved core determinants present in LPS molecules derived from a wide variety of gram-negative bacteria. This is, to our knowledge, the first published report in which monoclonal antibodies are used to demonstrate the extent of serological cross-reactivity among LPS present on Enterobacteriaceae. Although monoclonal anti-core antibodies of mouse origin might be expected to find limited usage in humans, these reagents should prove ideal in delineating the requisite affinity, epitope specificity, immunoglobulin class, etc., for the prevention and treatment of gram-negative bacteremia. Such information will be useful in preselecting human monoclonal antibodies for use in the therapeutics of gram-negative infection. Infect. Immun. 45:631-636) has also described mouse monoclonal antibodies reactive with epitopes shared by J5 lipopolysaccharide and lipopolysaccharide derived from a variety of gram-negative bacteria. Although the fine specificity of these monoclonal antibodies (anti-lipid A) differs from these described in our study (anti-core), the results of both studies lend support to the idea that one or more conserved epitopes are present on lipopolysaccharide molecules derived from serologically different gram-negative organisms.
